Literature DB >> 17001218

Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation).

Gerd Assmann1, Heike Benecke, Albrecht Neiss, Paul Cullen, Helmut Schulte, Kurt Bestehorn.   

Abstract

BACKGROUND: The aim of this study was to determine the achievement of National Cholesterol Education Program Adult Treatment Panel III goals in patients with primary hypercholesterolemia starting statin therapy in clinical practice. METHODS AND
RESULTS: Data were collected by 4401 physicians in private practice on 52 848 patients aged 35-65 years (46.3% women, 53.7% men). 56.1% of patients had no manifested atherosclerosis (primary prevention) among whom 34.9% of men and 0.5% of women had a 10-year coronary heart disease risk over 20% (high-risk) as calculated using the Prospective Cardiovascular Münster study (PROCAM) algorithm. After 6 weeks of statins, only 6.9% of these high-risk men and 4.6% of these high-risk women reached their low-density lipoprotein (LDL) cholesterol target of 2.6 mmol/l or below (100 mg/dl). Even after 9 months, only 8.0% of these men and 6.2% of these women achieved their LDL target. No fewer than 57.3% of treated women had a coronary risk below 10%, and 18.8% of women were already at target before statins were prescribed. Of patients 43.9% had manifest atherosclerosis (secondary prevention). After 6 weeks of therapy, only 12.9% of the women and 16.3% of the men in this secondary prevention group reached LDL target levels of 2.6 mmol/l or below. Even after 9 months, only 21.3% of men and 17.3% of women with manifest atherosclerosis reached target LDL.
CONCLUSIONS: Most high-risk patients do not achieve LDL targets. Overtreatment of low-risk groups is also very common.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001218     DOI: 10.1097/01.hjr.0000189805.76482.6e

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  11 in total

1.  [External control in medicine. Sense or nonsense].

Authors:  M Weber; O Zierenberg
Journal:  Internist (Berl)       Date:  2007-06       Impact factor: 0.743

Review 2.  Treating to protect: current cardiovascular treatment approaches and remaining needs.

Authors:  Michael Böhm; Christian Werner; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Journal:  Medscape J Med       Date:  2008-03-26

Review 3.  Residual risk in statin-treated patients: future therapeutic options.

Authors:  Catherine Y Campbell; Juan J Rivera; Roger S Blumenthal
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

4.  The effects of Hartcoach, a life style intervention provided by telephone on the reduction of coronary risk factors: a randomised trial.

Authors:  Chantal J Leemrijse; Liset van Dijk; Harald T Jørstad; Ron J G Peters; Cindy Veenhof
Journal:  BMC Cardiovasc Disord       Date:  2012-06-26       Impact factor: 2.298

5.  Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.

Authors:  Anselm K Gitt; Claus Jünger; Wenefrieda Smolka; Kurt Bestehorn
Journal:  Clin Res Cardiol       Date:  2010-06-03       Impact factor: 5.460

Review 6.  Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies.

Authors:  S Mitchell; S Roso; M Samuel; M Pladevall-Vila
Journal:  BMC Cardiovasc Disord       Date:  2016-04-26       Impact factor: 2.298

7.  Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease.

Authors:  Ralph Kwame Akyea; Joe Kai; Nadeem Qureshi; Barbara Iyen; Stephen F Weng
Journal:  Heart       Date:  2019-04-15       Impact factor: 5.994

8.  Lipid goal attainment and prescription behavior in asian patients with acute coronary syndromes: experience from a tertiary hospital.

Authors:  Calvin W Chin; F Gao; Tt Le; Rs Tan
Journal:  Clin Med Insights Cardiol       Date:  2013-03-12

9.  Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).

Authors:  D Devroey; R P Radermecker; B J Van der Schueren; B Torbeyns; R J Jaken
Journal:  Int J Clin Pract       Date:  2013-12-06       Impact factor: 2.503

10.  Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China.

Authors:  Qi Zhao; Ting-Yu Zhang; Yu-Jing Cheng; Yue Ma; Ying-Kai Xu; Jia-Qi Yang; Yu-Jie Zhou
Journal:  Lipids Health Dis       Date:  2020-07-31       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.